Bristol-Myers Squibb and Merck & Co are conducting several clinical trials in Korea for Opdivo and Keytruda, respectively, engaging in a fierce competition to expand their respective drug’s indications.
http://www.koreabiomed.com/news/articleView.html?idxno=1543
Immunotherapy developers engage in fierce competition to expand indications